Becton, Dickinson and Company $BDX Stock Bought by Cardinal Capital Management

Cardinal Capital Management boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 8.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,780 shares of the medical instruments supplier’s stock after purchasing an additional 2,810 shares during the quarter. Cardinal Capital Management’s holdings in Becton, Dickinson and Company were worth $6,584,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Foster Victor Wealth Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 1.4% during the third quarter. Foster Victor Wealth Advisors LLC now owns 61,476 shares of the medical instruments supplier’s stock valued at $11,726,000 after purchasing an additional 839 shares in the last quarter. Vest Financial LLC boosted its position in shares of Becton, Dickinson and Company by 14.9% in the 3rd quarter. Vest Financial LLC now owns 356,140 shares of the medical instruments supplier’s stock worth $63,749,000 after purchasing an additional 46,239 shares in the last quarter. Magnus Financial Group LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $250,000. Trifecta Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 59.0% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 62 shares in the last quarter. Finally, Axxcess Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 27.7% in the 3rd quarter. Axxcess Wealth Management LLC now owns 8,516 shares of the medical instruments supplier’s stock worth $1,524,000 after buying an additional 1,849 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,906 shares of company stock worth $1,265,855. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Barclays began coverage on Becton, Dickinson and Company in a research note on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price on the stock. Bank of America increased their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, August 31st. Finally, TD Cowen raised their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Trading Up 0.3%

Shares of NYSE BDX opened at $194.29 on Thursday. The firm’s 50 day moving average price is $184.73 and its 200-day moving average price is $164.54. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $195.99. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a market cap of $53.53 billion, a PE ratio of 58.52, a P/E/G ratio of 13.07 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. During the same quarter last year, the firm earned $3.68 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.